Trillium Asset Management LLC Decreases Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Trillium Asset Management LLC trimmed its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 9.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 94,694 shares of the medical research company's stock after selling 9,333 shares during the period. Trillium Asset Management LLC's holdings in Edwards Lifesciences were worth $7,010,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Wellington Management Group LLP raised its holdings in shares of Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares in the last quarter. State Street Corp increased its position in Edwards Lifesciences by 1.0% in the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company's stock worth $1,733,270,000 after purchasing an additional 256,538 shares during the last quarter. Geode Capital Management LLC raised its stake in Edwards Lifesciences by 2.2% during the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company's stock valued at $889,050,000 after purchasing an additional 284,918 shares in the last quarter. Fisher Asset Management LLC lifted its position in Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock valued at $723,664,000 after purchasing an additional 696,965 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $555,939,000. 79.46% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Ratings Changes

Several analysts have recently issued reports on EW shares. Canaccord Genuity Group upped their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. Morgan Stanley upped their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and boosted their target price for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group lifted their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Stock Up 1.4 %

NYSE EW traded up $0.97 on Monday, reaching $71.43. 3,603,111 shares of the stock traded hands, compared to its average volume of 4,612,597. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a fifty day moving average price of $71.42 and a 200-day moving average price of $70.38. The company has a market cap of $41.99 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Activity

In other news, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company's stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares of the company's stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 51,303 shares of company stock worth $3,715,776. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.